HORSHAM, PA — STRATA Skin Sciences Inc. (Nasdaq: SSKN) highlighted a February 2026 systematic review and meta-analysis that found the 308 nm excimer laser to be clinically effective in treating plaque psoriasis, the company announced.
The study, published in the Journal of Drugs in Dermatology by researchers from Georgetown University School of Medicine and MedStar Washington Hospital Center, reviewed clinical trials evaluating excimer laser therapy administered twice weekly for at least 10 sessions. Outcomes were measured using the Psoriasis Area and Severity Index, or PASI.
Across multiple studies, patients experienced statistically significant reductions in PASI scores. In one study of 32 patients, PASI scores declined from 11.47 to 5.08. In another study of 40 patients, scores decreased from 14.73 to 2.42. A 100-patient study reported a reduction from 13.70 to 2.10, while a 20-patient study showed scores falling from 12.02 to 4.09.
Patients generally achieved these results within 10 to 14 treatments over approximately five to seven weeks, according to the publication.
The analysis also examined minimal erythema dose-guided dosing, a method that calibrates ultraviolet B exposure to the lowest level that produces visible skin reddening after 24 hours. Treatment fluences in the reviewed studies ranged from approximately 200 to 600 mJ/cm² per session, with some protocols reaching higher totals.
“This meta-analysis reinforces what dermatologists have observed clinically — that properly calibrated, MED-guided Excimer Laser therapy provides effective, targeted treatment for plaque psoriasis,” Chief Executive Officer Dr. Dolev Rafaeli said in a statement.
STRATA manufactures excimer laser systems, including its XTRAC platform, used in dermatology practices. The company said the publication reflects continued research interest in targeted ultraviolet B therapies for inflammatory skin conditions.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.